2,4-diamino-7-methylquinazoline | 27018-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,4-diamino-7-methylquinazoline
• 英文别名: 7-methyl-quinazoline-2,4-diamine；2,4-Diamino-7-methyl-chinazolin；2,4-Quinazolinediamine, 7-methyl-；7-methylquinazoline-2,4-diamine
• CAS: 27018-16-2
• 化学式: C₉H₁₀N₄
• 分子量: 174.205
• InChiKey: ZUDXJVZWJQHECN-UHFFFAOYSA-N

物化性质

• 沸点：
  461.2±37.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氟-4-甲基苯胺 在 盐酸 、 copper(l) chloride 、 sodium nitrite 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 18.83h， 生成 2,4-diamino-7-methylquinazoline
  参考文献：
  名称：

  Hynes, John B.; Tomazic, Alenka; Parrish, Christie A., Journal of Heterocyclic Chemistry, 1991, vol. 28, # 5, p. 1357 - 1364

  摘要：

  DOI：

文献信息

• [EN] PRMT5 INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE LA PRMT5
  申请人：UNIV FLORIDA

  公开号：WO2020205660A1

  公开（公告）日：2020-10-08

  A series of PRMT5 inhibitor compounds are described. The compounds are useful as PRMT5 inhibitor compounds and in the treatment of PRMT5 mediated diseases, disorders, and symptoms thereof.

  本文介绍了一系列PRMT5抑制剂化合物。这些化合物可用作PRMT5抑制剂化合物，并用于治疗PRMT5介导的疾病、紊乱和其症状。
• Quinazoline Protein Tyrosine Phosphatase Inhibitors
  申请人：Berthel Steven Joseph

  公开号：US20090105477A1

  公开（公告）日：2009-04-23

  The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明涉及一种一般式I的氨基喹唑啉化合物:其中X是未取代或取代的苯基，或未取代或取代的5或6元杂环芳香环。本发明的化合物是PTP1B的有效抑制剂。因此，本发明还包括制备药物组合物和治疗或预防PTP-1B介导的疾病，包括糖尿病，肥胖症和糖尿病相关疾病的方法。
• [EN] GYRASE INHIBITORS<br/>[FR] INHIBITEURS DE GYRASE
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2011032050A2

  公开（公告）日：2011-03-17

  Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR5; R5 is H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR7, or CR8R9; R7 is H or C1-3 alkyl; R8 and R9 are each independently H or C1-3 alkyl; R2 is H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; R4 is H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0- 12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein R5 and R4 together may join to form a fused ring; and R6 is selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, halo C1-5 alkyl, halo C2-5 alkenyl, halo C2-5 alkynyl, C1-5 hydroxyalkyl, C1-5 alkyl chloride, C2-5 alkenyl chloride, and C2-5 alkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.
• Hynes, John B.; Tomazic, Alenka; Parrish, Christie A., Journal of Heterocyclic Chemistry, 1991, vol. 28, # 5, p. 1357 - 1364
  作者：Hynes, John B.、Tomazic, Alenka、Parrish, Christie A.、Fetzer, Oliver S.

  DOI：——

  日期：——